Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of β-catenin in prostate cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Fatty acid synthase (FASN), a key metabolic enzyme for liponeogenesis highly expressed in several human cancers, displays oncogenic properties such as resistance to apoptosis and induction of proliferation when overexpressed. To date, no mechanism has been identified to explain the oncogenicity of FASN in prostate cancer. We generated immortalized prostate epithelial cells (iPrECs) overexpressing FASN, and found that 14C-acetate incorporation into palmitate synthesized de novo by FASN was significantly elevated in immunoprecipitated Wnt-1 when compared to isogenic cells not overexpressing FASN. Overexpression of FASN caused membranous and cytoplasmic β-catenin protein accumulation and activation, whereas FASN knockdown by short-hairpin RNA resulted in a reduction in the extent of β-catenin activation. Orthotopic transplantation of iPrECs overexpressing FASN in nude mice resulted in invasive tumors that overexpressed β-catenin. A strong significant association between FASN and cytoplasmic (stabilized) β-catenin immunostaining was found in 862 cases of human prostate cancer after computerized subtraction of the membranous β-catenin signal (P<0.001, Spearman's ρ=0.33). We propose that cytoplasmic stabilization of β-catenin through palmitoylation of Wnt-1 and subsequent activation of the pathway is a potential mechanism of FASN oncogenicity in prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941 · cited 1×
“Although several mechanisms of FASNmediated oncogenicity have been hypothesized, clear pathways linking the activity of this enzyme and cancer have not been elucidated to date.(38,39) Here we hypothesized that the Wnt/b-catenin pathway is a potential mediator of FASN oncogenicity in the prostate.”
Wnt proteins are lipid-modified and can act as stem cell growth factors
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003) · Nature · doi:10.1038/nature01611 · Cited by 2,257
Fatty acid synthesis: a potential selective target for antineoplastic therapy
Kuhajda, F. P., Jenner, K., Wood, F. D., Hennigar, R. A., Jacobs, L. B., Dick, J. D., & Pasternack, G. R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6379 · Cited by 705
Interaction of Nuclear Receptors with the Wnt/β-Catenin/Tcf Signaling Axis: Wnt You Like to Know?
Mulholland, D. J., Dedhar, S., Coetzee, G. A., & Nelson, C. C. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0034 · Cited by 377 · cited 1×
“Therefore, b-catenin may play an important role in the maintenance/progression of castration-resistant prostate cancer.(44) Interestingly, high levels of FASN, Wnt-1 and b-catenin expression have been previously found to be associated with advanced, metastatic, hormone refractory prostate cancer.”
Chen, G., Shukeir, N., Potti, A., Sircar, K., Aprikian, A., Goltzman, D., & Rabbani, S. A. (2004) · Cancer · doi:10.1002/cncr.20518 · Cited by 283 · cited 4×
“Further, cytoplasmic stabilization of b-catenin has been previously described in apoptosis-resistant, hormone-refractory prostate cancer.(29,30) Thus, cytoplasmic stabilization of b-catenin can be considered a surrogate of activated b-catenin in prostate cancer.”
Influential
Cited by
Rysman, E., Brusselmans, K., Scheys, K., Timmermans, L., Derua, R., Munck, S., Van Veldhoven, P. P., Waltregny, D., Daniëls, V. W., Machiels, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3871 · Cited by 721
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
Self-citationDe novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy
Mashima, T., Seimiya, H., & Tsuruo, T. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605007 · Cited by 555
Fatty Acid Synthase As a Potential Therapeutic Target in Cancer
Flavin, R., Peluso, S., Nguyen, P. L., & Loda, M. (2010) · Future Oncology · doi:10.2217/fon.10.11 · Cited by 545
Self-citationA review on anti-cancer properties of Quercetin in breast cancer
Ezzati, M., Yousefi, B., Velaei, K., & Safa, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117463 · Cited by 356
Metadata
- Authors
- Fiorentino, M., Zadra, G., Palescandolo, E., Fedele, G., Bailey, D., Fiore, C., Nguyen, P. L., Migita, T., Zamponi, R., Di Vizio, D., Priolo, C., Sharma, C., Xie, W., Hemler, M. E., Mucci, L., Giovannucci, E., Finn, S., & Loda, M.
- Venue
- Laboratory Investigation
- Publisher
- Elsevier BV
- Published
- 2008-12
- Volume
- 88
- Issue
- 12
- Pages
- 1340-1348
- ISSN
- 0023-6837 (ISSN-L)
- OpenAlex
- W2077181241
- Cited by
- 136
- References
- 6
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.